Free Writing Prospectus
Filed Pursuant to Rule 433
Dated November 21, 2016
Registration Statement No. 333-209394
Relating to
Prospectus dated February 4, 2016
Zimmer Biomet Holdings, Inc. (rated Baa3 (negative) by Moody’s / BBB (stable) by S&P) has mandated BNP Paribas, HSBC, and RBC Capital Markets to arrange a series of fixed income investor meetings in Europe to occur November 29 – December 1. An inaugural Euro-denominated SEC-Registered senior unsecured benchmark transaction of 1-2 tranches will follow, with an expected maturity in the 7-12 year range. Relevant stabilization regulations including FCA/ICMA will apply. The Company intends to use the net proceeds of the transaction to repurchase certain series of its outstanding debt securities pursuant to a concurrent cash tender offer launched today.
Representing the Company will be:
Daniel Florin, Senior Vice President and CFO
Robert Marshall, Vice President, Investor Relations and Treasurer
Meeting Schedule:
| Tuesday, November 29: | London | 1x1’s and Group Lunch | ||||
| Wednesday, November 30: | Frankfurt | 1x1’s | ||||
| Munich | 1x1’s | |||||
| Thursday, December 1: | Amsterdam | Group Breakfast | ||||
| Paris | 1x1’s and Group Lunch |
Disclaimer
Zimmer Biomet has filed a registration statement (including a base prospectus) with the U.S. Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. Before you invest, you should read the preliminary prospectus supplement and final prospectus supplement, when available, and the accompanying base prospectus in that registration statement and other documents Zimmer Biomet has filed with the SEC for more complete information about Zimmer Biomet and this offering. You may obtain these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, Zimmer Biomet, any underwriter or any dealer participating in the offering will arrange to send you the preliminary prospectus supplement and final prospectus supplement, when available, and the accompanying base prospectus if you request it by calling toll-free 1-800-854-5674.
This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
A security rating is not a recommendation to buy, sell or hold securities and may be subject to suspension, reduction or withdrawal at any time by the assigning rating agency.
ANY DISCLAIMER OR OTHER NOTICE THAT MAY APPEAR BELOW IS NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED (OTHER THAN ANY STATEMENT RELATING TO THE IDENTITY OF THE LEGAL ENTITY AUTHORIZING OR SENDING THIS COMMUNICATION IN A NON-US JURISDICTION). SUCH DISCLAIMER OR OTHER NOTICE WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT BY BLOOMBERG OR ANOTHER EMAIL SYSTEM.
